Running Oak Capital LLC Grows Position in IQVIA Holdings Inc. (NYSE:IQV)

Running Oak Capital LLC grew its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 35.2% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 82,342 shares of the medical research company's stock after acquiring an additional 21,444 shares during the period. Running Oak Capital LLC's holdings in IQVIA were worth $14,517,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently modified their holdings of IQV. Howard Capital Management Inc. raised its stake in shares of IQVIA by 4.9% in the fourth quarter. Howard Capital Management Inc. now owns 1,147 shares of the medical research company's stock worth $225,000 after buying an additional 54 shares during the period. Continuum Advisory LLC raised its stake in IQVIA by 3.7% during the 4th quarter. Continuum Advisory LLC now owns 1,803 shares of the medical research company's stock worth $354,000 after acquiring an additional 64 shares during the period. ST Germain D J Co. Inc. boosted its position in shares of IQVIA by 66.1% in the first quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company's stock worth $34,000 after purchasing an additional 76 shares during the period. New York Life Investment Management LLC increased its stake in shares of IQVIA by 0.4% in the fourth quarter. New York Life Investment Management LLC now owns 23,086 shares of the medical research company's stock worth $4,537,000 after purchasing an additional 81 shares in the last quarter. Finally, Zions Bancorporation N.A. lifted its stake in shares of IQVIA by 55.2% during the 4th quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company's stock valued at $47,000 after buying an additional 85 shares in the last quarter. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several analysts recently issued reports on the company. Redburn Partners set a $188.00 target price on IQVIA in a research note on Friday, May 23rd. Truist Financial cut their target price on IQVIA from $263.00 to $216.00 and set a "buy" rating on the stock in a research report on Thursday, April 10th. Barclays decreased their target price on IQVIA from $170.00 to $165.00 and set an "equal weight" rating for the company in a research report on Wednesday, May 7th. UBS Group decreased their price objective on IQVIA from $255.00 to $185.00 and set a "buy" rating for the company in a report on Wednesday, May 7th. Finally, Citigroup restated a "neutral" rating on shares of IQVIA in a report on Thursday, May 22nd. Eight analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $226.32.

IQVIA Price Performance

IQV stock traded up $3.23 during mid-day trading on Tuesday, reaching $158.40. The company's stock had a trading volume of 420,538 shares, compared to its average volume of 1,969,999. The company has a current ratio of 0.82, a quick ratio of 0.82 and a debt-to-equity ratio of 2.19. The company's 50 day moving average is $148.30 and its two-hundred day moving average is $175.41. The stock has a market cap of $27.40 billion, a PE ratio of 21.58, a P/E/G ratio of 1.69 and a beta of 1.28. IQVIA Holdings Inc. has a fifty-two week low of $134.65 and a fifty-two week high of $252.88.

IQVIA (NYSE:IQV - Get Free Report) last issued its earnings results on Tuesday, May 6th. The medical research company reported $2.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.63 by $0.07. The company had revenue of $3.83 billion during the quarter, compared to analysts' expectations of $3.77 billion. IQVIA had a return on equity of 29.16% and a net margin of 8.61%. The firm's quarterly revenue was up 2.5% on a year-over-year basis. During the same period in the prior year, the business earned $2.54 EPS. Equities research analysts expect that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.